Safeguarding COVID-19 and cancer management: drug design and therapeutic approach
- Since cancer patients are at such a high risk for COVID-19, it is very important that physicians keep their treatment regimens for all medications under extreme control and very monitored
- It was identified that patients with hematologic cancers tend to have poorer outcomes than those with solid tumors and therefore they must be kept under constant surveillance for COVID-19 infection
- The purpose of this paper is to give a 1-year recap on cancer management techniques instituted during the COVID-19 pandemic
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
The implications of COVID-19 in radiation oncology in the United States
Safeguarding COVID-19 and cancer management: drug design and therapeutic approach
Cancer in COVID-19 Patients by Geographical Location
Hematological Cancers and COVID-19
COVID-19 Prevalence and Mortality in Patients with Cancer and the Effect of Primary Tumor Subtype and Patient Demographics
Clinical Considerations and Precautions for Cancer Patients During the COVID-19 Pandemic
Sickle Cell Disease and COVID-19
COVID-19 in Cancer Patients: Risk, Clinical Features, and Management
Safeguarding COVID-19 and cancer management: drug design and therapeutic approach